X
Details:
Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Liraglutide-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Biocon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Iran Expo
Not Confirmed
Contact Supplier
Details:
Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Adalvo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 09, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Tillomed Laboratories Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 16, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Liraglutide-Generic
Highest Development Status: UndisclosedProduct Type: Peptide
Recipient: Biocon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
Lead Product(s): Bevacizumab-maly,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Alymsys
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Mabxience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets.
Lead Product(s): Etonogestrel,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Myring
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Mithra Pharmaceuticals
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Agreement July 06, 2020
Iran Expo
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
